COPDX: an update of guidelines for the management of chronic obstructive pulmonary disease with a review of recent evidence

Long‐acting β2 agonists are an effective and convenient treatment for chronic obstructive pulmonary disease (COPD), but do not significantly improve lung function. The long‐acting anticholinergic tiotropium, which can be taken once daily, decreases exertional dyspnoea and increases endurance by reducing hyperinflation. The role in COPD of the combination of a long‐acting β2 agonist and a glucocorticoid in a single inhaler remains unclear. The minimum duration of an effective pulmonary rehabilitation program that includes exercise training is 6 weeks. Long‐term treatment with inhaled glucocorticoids may reduce the rate of decline in lung function, but the effect is small. Aminophylline should no longer be routinely used in acute exacerbations of COPD. Non‐invasive positive pressure ventilation (NPPV) reduces mortality and hospital stay in patients with acute hypercapnic ventilatory failure; it is also an effective weaning strategy for patients who require intubation. Further studies are required to clarify the role of NPPV in the long‐term management of stable COPD.

[1]  P. Poole,et al.  Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. , 2006, The Cochrane database of systematic reviews.

[2]  A. Cripps,et al.  Haemophilus influenzae oral vaccination against acute bronchitis. , 2000, The Cochrane database of systematic reviews.

[3]  J. Walters,et al.  Oral corticosteroids for stable chronic obstructive pulmonary disease. , 2005, The Cochrane database of systematic reviews.

[4]  P. Calverley,et al.  Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial , 2005, Thorax.

[5]  J. Connett,et al.  Smoking reduction and the rate of decline in FEV1: results from the Lung Health Study , 2005, European Respiratory Journal.

[6]  M. Decramer,et al.  Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial , 2005, The Lancet.

[7]  J. Steurer,et al.  Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. , 2004, Chest.

[8]  B. Make,et al.  Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD , 2004, European Respiratory Journal.

[9]  W. McNicholas,et al.  Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD , 2004, European Respiratory Journal.

[10]  P. Sagnier,et al.  Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. , 2004, Chest.

[11]  T. Lasserson,et al.  Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. , 2004, The Cochrane database of systematic reviews.

[12]  J. Wedzicha,et al.  Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. , 2004, The Cochrane database of systematic reviews.

[13]  E. R. Sutherland,et al.  Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis , 2003, Thorax.

[14]  A. Abernethy,et al.  Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea , 2003, BMJ : British Medical Journal.

[15]  T. Lasserson,et al.  Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease. , 2003, The Cochrane database of systematic reviews.

[16]  B. Rowe,et al.  Methylxanthines for exacerbations of chronic obstructive pulmonary disease. , 2003, The Cochrane database of systematic reviews.

[17]  R. Kaplan,et al.  Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial. , 2003, American journal of respiratory and critical care medicine.

[18]  P. Frith,et al.  The COPDX Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2003 , 2003, The Medical journal of Australia.

[19]  D. Mccrory,et al.  Anticholinergic bronchodilators versus beta2‐sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease , 2003 .

[20]  E. Walters,et al.  Self-management education for chronic obstructive pulmonary disease. , 2002, The Cochrane database of systematic reviews.

[21]  M. Meade,et al.  Noninvasive positive pressure ventilation as a weaning strategy for intubated adults with respiratory failure. , 2003, The Cochrane database of systematic reviews.

[22]  C. Strange,et al.  Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. , 2003, Annals of internal medicine.

[23]  J. Higgins,et al.  A systematic review of the use of opioids in the management of dyspnoea , 2002, Thorax.

[24]  A. Corrado,et al.  The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients , 2002, European Respiratory Journal.

[25]  M. Elliott.  Noninvasive ventilation in chronic ventilatory failure due to chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[26]  S. Yeh,et al.  Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. , 2002, Chest.

[27]  P. Ebeling,et al.  Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit , 2002, The Medical journal of Australia.

[28]  R. Casaburi,et al.  Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. , 2002, Chest.

[29]  R. Zuwallack,et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[30]  J. V. van Noord,et al.  Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium , 2002, European Respiratory Journal.

[31]  K. Hood,et al.  Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. , 2002, The Cochrane database of systematic reviews.

[32]  B. Smith,et al.  Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. , 2001 .

[33]  D. Mccrory,et al.  Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. , 2002, The Cochrane database of systematic reviews.

[34]  D. Brooks,et al.  Nutritional supplementation for stable chronic obstructive pulmonary disease. , 2002, The Cochrane database of systematic reviews.

[35]  Alan D. Lopez,et al.  The burden of disease and injury in Australia. , 2001, Bulletin of the World Health Organization.

[36]  R. Dahl,et al.  Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[37]  J. Finnerty,et al.  The effectiveness of outpatient pulmonary rehabilitation in chronic lung disease: a randomized controlled trial. , 2001, Chest.

[38]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[39]  Sally J. Singh,et al.  A randomised controlled trial of four weeks versus seven weeks of pulmonary rehabilitation in chronic obstructive pulmonary disease , 2001, Thorax.

[40]  J. Connett,et al.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[41]  B. Celli,et al.  Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. , 2000, Chest.

[42]  N. Payne,et al.  Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial , 2000, The Lancet.

[43]  Majid Ezzati,et al.  The burden of disease and injury in Australia , 2000 .